Development of a Costimulatory Molecule Signature to Predict Prognosis, Immune Landscape, and Response to Immune Therapy for Hepatocellular Carcinoma

Table 1

The clinicopathological characteristics of patients with HCC from TCGA and GEO database.

Characteristics		TCGA ()	GEO ()
Age
Gender	Male	165 (68.7%)	93 (81.5%)
	Female	75 (31.2%)	21 (18.4%)
Grade	I	29 (12.0%)
	II	53 (22.0%)
	III	95 (39.5%)
	IV	11 (4.5%)
TNM stage	I		55 (48.2%)
	II		35 (30.7%)
	III		21 (18.4%)
	IV		3 (2.6%)
T stage	I	118 (49.1%)
	II	53 (22.0%)
	III	59 (24.5%)
	IV	10 (4.1%)
M stage	M0	236 (98.3%)
	M1	4 (1.6%)
N stage	N0	236 (98.3%)
	N1	4 (1.6%)
BCLC stage	0		4 (3.5%)
	1		73 (64.0%)
	2		28 (24.5%)
	3		9 (7.8%)